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1. Introduction
  The morbidity of acute pancreatitis (AP) is 5.4-79.8/10 
million[1,2]. Severe acute pancreatitis (SAP) accounts for 
20%-30% with 10%-56% mortality[3-6]. 20%-40% of patients 
die from multiply organ failure induced by the systemic 
inflammatory response syndrome in the early stages[7-11]. 
Serum amyloid A (SAA) C-reactive protein (CRP), which is 
an acute phase response protein, increase after 4-6 hours 
of AP onset and sharply increase to a peak of more than 
1 000-2 000 times normal after 24-48 hours during the 
development of systemic inflammatory response syndrome 
(SIRS)[12]. Elevated SAA is 
involved in early inflammation and tissue damage through 
stimulating the cytokines TNF-a, IL-6 and IL-8 released 
from polymorphonuclea cells[13]. Mayer et al[14] found that 
SAA was a better early predictor of severity than CRP in 
acute pancreatitis.
    Chaiqinchengqi decoction (CQCQD) is modified from 
Dachengqi Decoction[15], which is a traditional Chinese 
medicine prescription and is traditionally used as 
purgatives in China. In recent decades, it has widely been 
used for AP[16]. Our study had found that CQCQD could 
effectively improve the symptoms, reduce diffusion and 
proliferation, reduce complications and mortality[14] through 
protecting organ function via the suppression of SIRS[17-19]. 
However, there are no studies concerning the effect on SAA.
  The aim of the present study was to investigate the effect 
of CQCQD on SAA in SAP patients.
 
Objective: To investigate the effect of Chaiqinchengqi decoction (CQCQD) on serum amyloid A 
(SAA) in severe acute pancreatitis (SAP) patients. Methods: Thirty-five participants enrolled 
and were randomly assigned into either a treatment condition (n=17, treated with CQCQD) or 
a control condition (n=18, treated with placebo) 24 hours following the onset of the disease. 
No statistical difference was observed in either group at baseline. Upon admission,  the Acute 
Physiology and Chronic Health Evaluation score 栻 (APACHE 栻), SAA, serum C-reactive protein 
(CRP) and interleukin-6 (IL-6) were measured, as well as on the first, 3rd and 7th day and were 
compared between the two groups. Organ complications, infection, operation rate, mortality and 
hospital stay were also compared. Results: The duration of acute respiratory distress syndrome, 
acute hepatitis, acute renal failure, gastrointestinal failure and blood coagulation dysfunction 
were shorter in the treatment group than in those in the control group (P < 0.05). The secondary 
infection rates and the hospital fees in the treatment group were lower than those in the control 
group (P < 0.05) as well as length of hospital stay (P < 0.01). After 3 days of hospitalization, the 
APACHE栻, score SAA levels, serum CRP and IL-6 in the treatment group was lower than those 
in the control group (P < 0.05). SAA was positively correlated with serum CRP (R = 0.346, P = 
0.042), Ranson score (R = 0.442, P = 0.008) and serum IL-6 (R=0.359, P =0.034). The area under 
the receiver operating characteristic curve of admission SAA predict pancreatic necrosis (PN) was 
0.815 (95% CI: 0.625-0.954; P =0.006). The best cut-off value of admission SAA was 7.85 mg/L with 
the sensitivity 84.6% and specificity 68.2%. Conclusions: The CQCQD can reduce the duration 
of organ damage through lowering the SAA in SAP patients and the SAA can early predict the PN 
and severity of SAP patients. 
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2. Materials and methods
2.1. Inclusive criteria 
  Male and female SAP patients (曒18 and 曑70 years of 
age) hospitalized within 24 hours of onset of symptoms 
were enrolled. The diagnostic criteria formulated for SAP 
at the Bangkok World Congress of Gastroenterology 2002 in 
Thailand were adopted[2].  
 
2.2. Exclusion criteria 
  Patients with any of the following were excluded from 
the study: concurrent sepsis or pancreatic infection or 
peripancreatic infection caused by a second disease; 
those sent directly to the intensive care unit for multiorgan 
failure, post-encoscopic Retrograde Cholangio-Pancreatography or 
traumatic or operative pancreatitis; pregnancy, malignancy, 
immunodeficiency or moribund patients regardless of cause 
within 48 hours prior to enrollment.
 
2.3.  Withdrawal criteria
 Patients who had been enrolled in the study could be 
withdrawn if: the patient died or received an operation 
because they were not responsive to intensive care treatment 
within 72 hours upon admission; the patient could not 
continuously receive traditional Chinese medicine treatment 
due to adverse reactions or they strongly requested to 
withdraw from the study due to other reasons.
 
2.4. Preparation of CQCQD
  Chinese medicinal herbs in CQCQD were provided by West 
China Hospital and included Chaihu (Radix bupleuri) 15 g, 
Huangqin (Radix scutellariae) 15 g, Houpu (Cortex magnoliae 
officinalis) 15 g, Zhishi (Fructus aurantii immaturus) 15 g, 
Dahuang (Radix et rhizoma rhei) 15 g, Danpi (Cortex moutan) 
9 g, Yuanhu (Rhizoma corydalis), Chuanlian (Chinaberry fruit) 
9 g, Gansui (Radix kansui) 0.2 g and Mangxiao (Natrii sulfas) 
10 g. Every decoction was made into particle preparation (2 
bags伊10 g). Before the experiment, the particle preparation 
of CQCQD was prepared for a solution (200 mL/10 g). 
  The placebo was similar with CQCQD in packaging, shape, 
smell, color and so on.
2.5. Study Design
  The study was conducted in West China Hospital of 
Sichuan University. Patients enrolled in the study were 
randomly assigned into the study group or the control group 
by random numbers (1:1) generated using SAS software. 
The patients in the treatment group were administered with 
QCQCQD by gastric perfusion (50 mL/2 h伊7) and retention 
enema (200 mL/6 h伊7). Patients in the control group received 
the same volume and concentration via the same methods as 
the treatment group with placebo treatment.
  All patients received standardized comprehensive 
treatment by the same group of physicians as follows[20,21]: 
intensive care, oxygen inhalation, fluid resuscitation 
to correct fluid losses in the third space and maintain 
adequate intravascular volume as well as homeostasis of 
electrolyte and acid-base, fasting and gastrointestinal 
decompression as well as H2-blocking agent or proton pump 
inhibitor, prophylactic antibiotics for 7-14 days, nutritive 
administration, respirator administration if hypoxemic 
respiratory failure developed, and symptomatic treatment. 
Patients were observed during their hospital stay. Follow-up 
evaluations, including an abdominal ultrasound and short 
questionnaire regarding abdominal pain and daily activities, 
were performed for up to 3 months following discharge.
  The following parameters were measured: SAA, serum CRP, 
serum IL-6, the initial Balthazar’s CT score, the APACHE 
栻 score obtained upon admission as well as those obtained 
onthe first, 3rd and 7th day, incidence and duration of 
complications including acute respiratory distress syndrome 
(ARDS), acute renal failure (ARF), acute hepatitis (AH), 
encephalopathy (EP), gastrointestinal failure (GF), blood 
coagulation dysfunction (BCD): infection rate, hospital stay, 
operation rate and mortality.
  The concentration of SAA and serum IL-6 were measured 
with ELISA kits (ADL, United States of America) according to 
the instructions by the manufacturers.
  Diagnostic criteria for organ failure were as follows[22,23]:
 AHF: hypotension, heart rate曑54 b.p.m., or >130 b.p.m., 
mean arterial pressure曑 6.5 kPa (49 mmHg);
  ARDS: dyspnea, R > 35 b.p.m., PaO2 < 8.0 kPa (60 mmHg);
  ARF: urinary volume < 480 mL/24 h (20 mL/h) or serum 
creatinine 曒177 毺mol/L (2 mg/dL); 
  AH: serum bilirubilin 曒34 毺mol/L, ALT > 2 times of the 
upper normal limit;
  EP: neurologic failure if mental confusion, delirium or 
coma;
  GF: paralytic ileus, hematemesis or melena, bleeding 
volume > 1 000 mL; 
  BCD: platelet count was 曑 80伊 10
9/L, PT > 16 s, APTT > 45 
s, FIB < 1.5毺2.0 g/L.
2.6. Statistical analysis
  Data were expressed as mean暲SD or percentage. Data in 
normal distribution was analyzed using t-test; data in non-
normal distribution was analyzed using Wilcox on rank sum 
test. Categorical data was analyzed using chi-square test. 
For calculation of cut-off values, positive predictive values 
(PPV), area under the curve (AUC), sensitivity and specificity, 
and receiver-operator characteristics (ROC) analyses were 
performed. P < 0.05 was considered statistically significant.
  The medical ethics committee of West China Hospital 
at Sichuan University approved this study. All patients 
gave their informed consent, and the study was conducted 
according to the recent principles of the Declaration of 
Helsinki (World Medical Association, 2000).
3. Results
3.1. Clinical characteristics
  From March 1, 2009 to July 31, 2009, there were 389 patients 
with AP hospitalized in our Center who were initially 
screened for entry into the study. A total of 78 patients met 
the diagnostic criteria of SAP, of which 35 patients who 
met the selective criteria of the study were enrolled into 
the study (17 in treatment group and 18 in control group). 
No patients were withdrawn due to loss of follow-up. No 
patients had verified evidence of adverse effects. 
  There were no statistical differences between the two 
groups in sex, age or etiology (P > 0.05), nor in the 48-h 
Ranson score, admission APACHE II score and Balthazar CT 
scores in the initial stage of hospitalization (P > 0.05, Table 1).
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Table 1
Baseline data of the control group and the treatment 
group. 
Baseline data Control group
 (n=17)
Treatment group
 (n=18)
Sex(M/F) 11/9 9/8
Age (year) 48.5暲12.2 49.4暲8.5
Pathogen [(n)%] Cholelithiasis 5(29.4) 6(33.3)
Alcoholism 3(17.6) 2(11.1)
Hyperlipidemia 3(17.6) 4(22.2)
Idiopathic 6(35.3) 6(33.3)
Ranson score (mean暲SD)   4.2暲1.9   3.8暲1.5
Admission APACHE II score (mean暲 
SD)
10.3暲6.7   8.9暲4.3
Balthazar CT score (mean暲SD)   4.9暲1.2   4.9暲1.5
3.2. Complication
  There were no statistical differences between the two 
groups in the incidence of organs dysfunction (P > 0.05, 
Table 2), but the duration of ARDS, ARF, AH, GF and 
BCD in treatment group were significantly shorter than 
those in the control group (P < 0.05, Table 3). 
Table 2  
Incidence of the complication in the treatment and the control 
group[(n)%].
Complication  Treatment group (n=17) Control group(n=18)
Shock   3(17.7)   6(33.3)
ARDS 10(58.8) 14(77.8)
ARF   3(17.7)   3(16.7)
AH   6(35.3)   8(44.4)
EP   2(11.8)   2(11.1)
BCD   4(23.5)   3(16.7)
GF   6(35.3)   7(38.9)
Table 3   
Duration of complications in the treatment and the control group (d).
Complication  Treatment group (n=17) Control group(n=18)
Shock 1.7暲1.2   3.5暲2.4
ARDS 2.8暲1.8   5.8暲3.9
a
ARF 2.1暲0.5   5.3暲2.3
a
AH 2.5暲2.1   5.2暲1.9
a
GF 4.9暲2.5   8.2暲5.1
a
BCD 2.5暲1.3 16.7暲9.0
a
EP 3.7暲1.5   4.3暲1.8
a:P < 0.05 vs. treatment group.
Table 4   
Prognosis in the treatment group and the control group.
Prognosis  Treatment group
 (n=17)
Control group
(n=18)
Secondary infection [(n)%] 2(11.8) 8(44.4)b
Operation [(n)%] 0(0) 1(5.6)
Hospital stay (mean暲 SD) 17.8暲8.8 27.8暲7.9
d
Death [(n)%] 1(5.9) 1(5.6)
Hospital fees (RMB) 31 891.0暲18 895.4 64 365.5暲51 377.6
f
b: P < 0.01 vs. treatment group; d: P < 0.01 vs. treatment group; f: P < 
0.01 vs. treatment group.
3.3. Prognosis
  Secondary infection rates and hospital fees were lower 
in the treatment group than those in the control group (P 
< 0.05). Hospital stay was also shorter in the treatment 
group (P < 0.01, Table 4).
3.4. APACHE栻 score, SAA, serum IL-6 and serum CRP 
in the treatment group and control group 
  There were no statistical differences between the two 
groups in the admission and first-day APACHE栻 score, 
SAA, serum IL-6 and CRP (P > 0.05). After 3 days of 
hospitalization,, the APACHE栻 score, SAA, serum IL-6 
and CRP in the treatment group were significantly lower 
than those in the control group (P < 0.05).
  There were no statistical differences in admission and 
first-day APACHE栻 between the treatment group and 
the control group (9.3暲4.4 vs. 11.5暲6.7; 8.9暲4.9 vs. 10.7暲
5.7, P > 0.05). On the 3rd and 7th day, the APACHE栻 in 
the treatment group was lower than the control group (6.5
暲3.5 vs. 10.3暲3.9; 5.6暲3.5 vs. 9.5暲4.4, P < 0.05).
  There were no statistical differences in admission and 
first-day serum IL-6 between the treatment group and 
the control group (162.5暲48.1 vs. 156.1暲53.3; 151.3暲34.9 
vs. 153.4暲34.5, P>0.05). But on the 3rd and 7th day, the 
serum IL-6 in the treatment group was lower than those 
in the control group (119暲33.1 vs. 149.8暲36.1; 87.3暲30.9 
vs. 129.7暲34.7, P < 0.05).
  There were no statistical differences in admission and 
the first-day SAA between the treatment group and the 
control group (7.2暲3.7 vs. 7.8 暲2.5; 6.2暲2.3 vs. 6.5暲3.9, P 
> 0.05). On the 3rd and 7th day, the SAA in the treatment 
group was lower than those in the control group (4.9暲2.5 
vs. 6.3暲2.3;  4.6暲2.2 vs. 6.1暲3.1, P < 0.05).
  There were no statistical differences in admission and 
first-day serum CRP between the two groups (179.8暲43.1 
vs. 181.3暲46.0; 183.2暲45.3 vs. 185.1暲42.7, P>0.05). On 
the 3rd and 7th day, the SAA in the treatment group was 
lower than those in the control group (120.1暲47.9 vs. 156.9
暲45.9; 91.5暲33.6 vs. 138.7暲36.2, P<0.05).
3.5. Relationship of serum SAA with severity index of SAP
  Correlation analysis found that the SAA was positively 
correlated with serum CRP (R=0.346, P=0.042), Ranson 
score (R=0.442, P=0.008) and serum IL-6 (R=0.359, 
P=0.034, Figure 1). In the 35 SAP patients, the receiver 
operating characteristic (ROC) curve of admission serum 
SAA was analyzed with pancreatic necrosis as a positive 
indicator and non-pancreatic necrosis as a negative 
indicator according the result of enhance CT. The AUC 
was 0.815 (95% CI: 0.625-0.954; P = 0.006, Figure 2). The 
PPV analysis also found that the best cut-off value of 
admission SAA predicting the pancreatic necrosis of was 
7.85 mg/L with the sensitivity 84.6% and specificity 68.2%.
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Figure 2. ROC curve of admission SAA predicting pancreatic 
necrosis.
4. Discussion
  The mortality of SAP was 10%- 30%[1-4]. 20%-40% of 
those patients died in MODS induced by SIRS in the early 
stage[5-9]. In the course of occurrence and development 
of SIRS, the SAA is one of the acute phase response 
proteins comprising a family of apolipoproteins which are 
mainly synthesized in the liver in response to cytokines 
following acute-phase stimulus such as physical injury or 
infection[24,25], increased after 4-6 hours of disease onset, 
and sharply rose to a peak of more than 1 000-2 000 times 
normal after 24-48 hours[12]. The elevated SAA involved in 
early inflammation and tissue damage through stimulating 
the elevation of inflammatory factors such as TNF-a, IL-6 
and IL-8 released from polymorphonuclea cell. The SAA in 
the patient complicated with pancreatic necrosis, pancreatic 
necrosis infection or MODS was higher and a marker of early 
prediction of severity of AP[14,26-33]. The results of our study 
were consistent with this conclusion. We found that the SAA 
was positively correlated with serum IL-6 (R = 0.359, P = 
0.034) and the severity index of SAP including the serum CRP 
(R = 0.346, P = 0.042), APACHE II score (R = 0.367, P = 0.030) 
and Ranson score (R = 0.442, P = 0.008). The ROC curve of 
admission SAA was analyzed with pancreatic necrosis as 
positive indicators and non- pancreatic necrosis as negative 
indicators according to the result of the enhanced CT; the 
area under the ROC curve is 0.815 (95% CI: 0.625-0.954; 
P=0.006). The PPV analysis also found that the best cut-off 
value of admission SAA predicting the pancreatic necrosis of 
is 7.85 mg/L with the sensitivity 84.6% and specificity 68.2%. 
The results indicated that the SAA not only can predict the 
PN but also the severity in SAP patients.
  CQCQD modified from Dachengqi Decoction (Houpu, 
Zhishi, Dahuang and Mangxiao) was the commonly used 
herbal prescription in the treatment of SAP in the early 
stage in China. It can effectively improve the symptoms 
and signs, reduce proliferation and reduce the incidence 
of complications and mortality of SAP patients through 
protecting intestinal mucosal barrier and organ function, 
suppressing SIRS, helping the restoration of injured pancreas 
and the absorption of peripancreatic inflammation and 
improving microcirculation of pancreas. In this study, we 
also found that the duration of ARDS, ARF, AH, GF and BCD 
in the treatment group were shorter than those in the control 
group (P < 0.05). The secondary infection rates and the 
Hospital fees in the treatment group were lower than those 
in the control group (P < 0.05) as well as the length of the 
hospital stay (P < 0.01).
  Based on the therapeutic effect of CQCQD on SAP patients 
and the status of SAA in SIRS and organ injury, the present 
study on 35 SAP patients was to investigate the hypothesis 
that CQCQD could reduce the SAA, relive the SIRS, and then 
cut down the MODS of SAP patients. Through comparison 
with the serum CRF and the APACHE II score, an important 
diagnostic and predictable severity indicator of SAP[34-
36], we found that the SAA and serum CRP and IL-6 and 
the APACHE II score atadmission and the first day were 
not significantly different between the CQCQD treatment 
group and the control group. However, on the 3rd day and 
7th day after admission, the SAA and serum CRP and IL-6 
concentration and the APACHE II score in the treatment 
group were lower than those in the control group (P < 0.05). 
This result indicated that mechanism of the CQCQD reliving 
the severity of SAP might result from reducing the SAA.
  In conclusion, our study indicated that CQCQD can reduce 
the severity and shorten the duration of organ dysfunction of 
SAP by lowering the SAA. However, due to the limitations of 
sample size, our study failed to find an impact on incidence 
and mortality. In addition, the specific mechanism of CQCQD 
reducing the SAA is still in need of further study.
300.00
200.00
100.00
2.00        4.00          6.00          8.00        10.00
2.00        4.00          6.00          8.00        10.00
2.00        4.00          6.00          8.00        10.00
8.00
6.00
4.00
2.00
400.00
300.00
200.00
100.00
SAA SAA SAA
CRP
Ranson score
IL-6
a
b
c
Figure 1. Scatter diagram of admission SAA and serum IL-6 (a), Ranson score (b) and admission serum CRP (C).
Wei Wu et al./Asian Pacific Journal of Tropical Medicine (2012)901-905 905
Conflict of interest statement
  We declare that we have no conflict of interest.
References 
[1]  Goldacre MJ, Roberts SE. Hospital admission for acute pancreatitis 
in an English population, 1963-98: database study of incidence 
and mortality. BMJ 2004; 328: 1466-1469.
[2] Toouli J, Brooke-Smith M, Bassi C, Carr-Locke D, Telford 
J, Freeny P, et al. Guidelines for the management of acute 
pancreatitis. J Gastroenter Hepat 2002; 17: S15-S39.
[3]  Peng YS, Wu CS, Chen YC, Lien JM, Tian YC, Fang JT, et al. 
Critical illness-related corticosteroid insufficiency in patients with 
severe acute biliary pancreatitis: a prospective cohort study. Crit 
Care 2009; 13: R123.
[4]  Tonsi AF, Bacchion M, Crippa S, Malleo G, Bassi C. Acute 
pancreatitis at the beginning of the 21st century: the state of the 
art. World J Gastroenterol 2009; 15: 2945-2959.
[5]  Ishikawa T, Imai M, Kamimura H, Ushiki T, Tsuchiya A, Togashi 
T, et al. Therapeutic efficacy of continuous arterial infusion of the 
protease inhibitor and the antibiotics and via celiac and superior 
mesenteric artery for severe acute pancreatitis--pilot study. 
Hepatogastroenterology 2009; 56: 524-528.
[6]  Jha RK, Ma Q, Sha H, Palikhe M. Acute pancreatitis: a literature 
review. Med Sci Monit 2009; 15: RA147-RA156.
[7]  Mole DJ, Olabi B, Robinson V, Garden OJ, Parks RW. Incidence 
of individual organ dysfunction in fatal acute pancreatitis: analysis 
of 1 024 death records. HPB (Oxford) 2009; 11: 166-170. 
[8]  Pitchumoni CS, Patel NM, Shah P. Factors influencing mortality in 
acute pancreatitis: can we alter them? J Clin Gastroenterol 2005; 
39: 798-814. 
[9]  Darvas K, Fut仵 J, Okr侬s I, Gondos T, Csom仵s A, Kupcsulik P. 
Principles of intensive care in severe acute pancreatitis in 2008. 
Orv Hetil 2008; 149: 2211-2220. 
[10] Liu X, Liu Q, Pan C. Early preventive treatment for severe acute 
pancreatitis combined with lung injury. Chin J Traumatol 2002; 
5: 190-192. 
[11] Roseano M, Lovadina S, Calligarisl, Ursic I, Cuviello A, Liguori G. 
The multidisciplinary management of acute pancreatitis:a review 
of 244 cases. Ann Ital Chir 2004; 75: 443-453.
[12] Uriele-shoval S, Linke RP, Matzner Y. Expression and function of 
serum amyloid A(SAA), a major acute phase protein,in normal and 
disease states. Curr Opin Hematol 2000; 7: 64-69.
[13] Badolato R, Wang JM, Stornello SL, Ponzi AN, Duse M, Musso T. 
Serum amyloid A is an activator of PMN antimicrobial functions: 
induction of degranulation, phagocytosis, and enhancement of 
anti-Candida activity. J Leukoc Biol 2000; 67: 381-386.
[14] Mayer JM, Raraty M, Slavin J, Kemppainen E, Fitzpatrick J, 
Hietaranta A, et al. Serum amyloid A is a better early predictor of 
severity than C-reactive protein in acute pancreatitis. Br J Surg 
2002; 89: 163-171.
[15] Wang ZC, Xue P, Huang ZW. Effect of an early application of 
chaiqin chengqi decoction in treating severe acute pancreatitis 
complicated with acute respiratory distrees syndrome. Zhongguo 
Zhong Xi Yi Jie He Za Zhi 2009; 29: 322-324.
[16] Liu XB, Jiang JM, Huang ZW, Tian BL, Hu WM, Xia Q, et al. 
Clinical study on the treatment of severe acute pancreatitis by 
integrated traditional Chinese medicine and Western medicine. 
Sichuan Da Xue Xue Bao Yi Xue Ban 2004; 35: 204-208.
[17] Li YH, Huang ZW, Xue P, Guo J, He FQ, You Z, et al. Effects 
of Chaiqin Chengqi Decoction on activation of nuclear factor-
kappaB in pancreas of rats with acute necrotizing pancreatitis. 
Zhong Xi Yi Jie He Xue Bao 2008; 6: 180-184.
[18] Xue P, Huang ZW, Zhang HY, Xia Q, Li YH, Wang ZC, et al. 
Impact of Chai Qin Cheng Qi Decoction on cholinergic anti-
inflammatory pathway in rats with severe acute pancreatitis. 
Sichuan Da Xue Xue Bao Yi Xue Ban 2006; 37: 66-68.
[19] Xue P, Deng LH, Zhang ZD, Yang XN, Xia Q, Xiang DK, Huang 
L, Wan MH. Effect of Chaiqinchengqi decoction on sarco/
endoplasmic reticulum Ca2+-ATPase mRNA expression of 
pancreatic tissues in acute pancreatitis rats. World J Gastroenterol 
2008; 14: 2343-2348.
[20] Xue P, Deng LH, Xia Q, Zhang ZD, Hu WM, Yang XN, et al. 
Impact of alanyl-glutamine dipeptide on severe acute pancreatitis 
in early stage. World J Gastroenterol 2008;14: 474-478. 
[21] Xue P, Deng LH, Zhang ZD, Yang XN, Wan MH, Song B, et al. 
Effect of antibiotic prophylaxis on acute necrotizing pancreatitis: 
Results of a randomized controlled trial. J Gastroenterol Hepatol 
2009; 24: 736-742. 
[22] Pancreatic Surgery Association of Chinese Medical Association. 
The criteria of clinical diagnosis and classification system for 
acute pancreatitis (the second project, 1996). Zhonghua Waike 
Zazhi 1997; 35: 773-775.
[23] Xue P, Deng LH, Zhang ZD, Yang XN, Wan MH, Song B, et al. 
Infectious complications in patients with severe acute pancreatitis. 
Dig Dis Sci 2009; 54: 2748-2753.
[24] Shimetani N, Shimetani K, Mori M. Levels of three inflammation 
markers, C-reactive protein, serum amyloid A protein and 
procalcitonin, in the serum and cerebrospinal fluid of patients with 
meningitis. Scand J Clin Lab Invest 2001; 61: 567-574.
[25] Kovatchev BP, Farhy LS, Cao H, Griffin MP, Lake DE, Moorman 
JR. Sample asymmetry analysis of heart rate characteristics with 
application to neonatal sepsis and systemic inflammatory response 
syndrome. Pediatr Res 2003; 54: 892-898.
[26] Shimetani N, Shimetani K, Mori M. Clinical evaluation of the 
measurement of serum procalcitonin: comparative study of 
procalcitonin and serum amyloid A protein in patients with high 
and low concentrations of serum C-reactive protein. Scand J Clin 
Lab Invest 2004; 64: 469-474.
[27] Rau B, Schilling MK, Beger HG. Laboratory markers of severe 
acute pancreatitis. Dig Dis 2004; 22: 247-257.
[28] Al Mofleh IA. Severe acute pancreatitis: pathogenetic aspects and 
prognostic factors. World J Gastroenterol 2008; 14: 675-684.
[29] Rau B, Steinbach G, Baumgart K, Gansauge F, Gr俟nert A, 
Beger HG. Serum amyloid A versus C-reactive protein in acute 
pancreatitis: clinical value of an alternative acute-phase reactant. 
Crit Care Med 2000; 28: 736-742.
[30] Ofusori DA, Adejuwon AO. Histopathological studies of acute 
and chronic effects of Calliandra portoricensis leaf extract on the 
stomach and pancreas of adult Swiss albino mice. Asian Pac J 
Trop Biomed 2011; 1(3): 182-185.
[31] Ramesh B, Karuna R, Sreenivasa RS, Haritha K, Sai MD, Sasis 
BRB, et al. Effect of Commiphora mukul gum resin on hepatic 
marker enzymes, lipid peroxidation and antioxidants status in 
pancreas and heart of streptozotocin induced diabetic rats. Asian 
Pac J Trop Biomed 2012; 2(11): 895-900.
[32] Adefegha SA, Oboh G. In vitro inhibition activity of polyphenol-
rich extracts from Syzygium aromaticum (L.) Merr. & Perry (Clove) 
buds against carbohydrate hydrolyzing enzymes linked to type 2 
diabetes and Fe2+-induced lipid peroxidation in rat pancreas. 
Asian Pac J Trop Biomed 2012; 2(10): 774-781.
[33] Oezcueruemez-Porsch M, Kunz D, Hardt PD, Fadgyas T, Kress 
O, Schulz HU, et al. Diagnostic relevance of interleukin pattern, 
acute-phase proteins, and procalcitonin in early phase of post-
ERCP pancreatitis. Dig Dis Sci 1998; 43: 1763-1769.
[34] Glisic T, Sijacki A, Vukovic V, Subotic A. Bernard Organ Failure 
Score in estimation of most severe forms of acute pancreatitis. Srp 
Arh Celok Lek 2009; 137: 166-170.
[35] Wig JD, Bharathy KG, Kochhar R, Yadav TD, Kudari AK, Doley 
RP, et al. Correlates of organ failure in severe acute pancreatitis. 
JOP 2009; 10: 271-275.
[36] Novovic S, Andersen AM, Ersb旾ll AK, Nielsen OH, Jorgensen 
LN, Hansen MB. Proinflammatory cytokines in alcohol or gallstone 
induced acute pancreatitis. A prospective study. JOP 2009; 10: 
256-262.
